-14.6%
CRH vs MRNA
+511.3%
-525.9%
-29.8%
Performance
Returns, benchmark comparison, and relative performance.
Performance by timeframe
Returns for 1y.
| Period | Portfolio | MRNA | Excess | Alpha |
|---|---|---|---|---|
| 1D | +2.4% | -2.2% | +4.6% | +2.5% |
| 7D | -1.7% | +5.5% | -7.1% | -1.8% |
| 30D | -5.4% | +158.7% | -164.1% | -9.3% |
| 3M | -11.2% | +182.1% | -193.3% | -16.0% |
| 6M | -15.8% | +151.8% | -167.7% | -20.2% |
| YTD | -23.6% | +393.6% | -417.2% | -29.3% |
| 1Y | -14.6% | +499.5% | -514.1% | -23.1% |
| All | -14.6% | +511.3% | -525.9% | -23.1% |
Cumulative growth
Daily Returns
Daily percentage return beside MRNA.
Daily Out/Under-Performance
Portfolio return minus MRNA return. Positive bars indicate outperformance.
Daily Alpha
Portfolio daily return minus β × MRNA return. Early observations use the first valid beta; later observations use the trailing beta estimated for each date.
Cumulative Out/Under-Performance
Relative wealth over 1y: compounded portfolio wealth divided by compounded MRNA wealth, less one. Both series rebase at the selected span's start.
Cumulative Alpha
Compounded beta-adjusted residual returns apply the first valid beta to early observations, then the trailing beta ending on each date.
Updating return analytics…
1y analysis · Full analysis span regression · 6 months rolling